65,437 trials
Prostate Cancer
Primary: Number of Patients Who Achieve a PSA ≤ 4ng/mL After Seven Months of Protocol Treatment in Each Arm — 16; 32 Participants — p=0.87
Plaque Psoriasis
Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants
Muscular Dystrophies
Primary: Change From Baseline in Muscle Function Using the 6 Minute Walking Distance (6MWD) Test Assessed at Week 48 — -52.65; -42.32 Meters — p=0.415
Retinitis Pigmentosa
Primary: ETDRS Visual Acuity (High Contrast) — -0.02; 0.11 log unit
Bone Diseases · Spine Cancer · Spine Osteoarthritis
Primary: Soft Tissue Dissecting Time — 38.6; 34 minues
Influenza
Primary: Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies — 154; 121 Participants
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months — -1.4 units on a scale
Influenza
Primary: Number of Participants With Seroconversion to A/California/07/2009 (H1N1) — 41; 21 Participants
Anesthesia
Primary: Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9 — 20.98; 3.72; 2.42; 0.58 Minutes
Cardiovascular Diseases · Cardiac Surgery
Primary: Exercise Capacity Assessed as Peak Oxygen Consumption at 4 Weeks After Randomisation — 0.92; 0.87 mL/Kg/minute — p=0.63
Prostate Cancer
Primary: The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. — 126; 87; 88; 34 Participants
Peripheral Arterial Disease
Primary: Clinical Cohort ITT - Primary Effectiveness Endpoint — 1263 Participants
Non-target Heterologous Effects of Vaccines · Vaccine Interactions
Primary: Effect on Interferon (IFN)-Gamma : Interleukin (IL)-4 Ratio in Plasma — 1.48; 1.44; 0.46 ratio of cytokines in pg/mL
Toothache
Primary: Mean of Pain Intensity Based on the Visual Analogue Scale (VAS) — 37.45; 34.95; 38.84; 17.15 Scores on a Scale
Asthma
Primary: Number of Pediatric Participants With Problems Understanding Item Wording-Round 1 Interviews — 0; 0 Participants